Article Correctness Is Author's Responsibility: Results from the ABSORB IV trial reported at TCT 2017

(Cardiovascular Research Foundation) Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).